Condition: Schizophrenia · Psychosis · Sponsor: Jimmi Nielsen
The outline of the current project is to establish a cohort of patients with treatment refractory schizophrenia eligible for clozapine, to identify clinical and biological characteristics of clozapine responding patients. Patients will be offered treatment with clozapine according to national clinical guidelines. Before clozapine is initiated, patients will be offered a thoroughly neurobiological examination, and re-examination will be carried out after 12 weeks of treatment. The primary focus of the examinations will be immunological markers and autoantibodies in the blood and cerebrospinal fluid, permeability of the blood-brain barrier and magnetic resonance imaging of structural, neurochemical and functional brain changes.
This description comes directly from the study's public registry record.
Jimmi Nielsen, PhD · 4538640885 · jimmi.nielsen@regionh.dk
Mette Nielsen, PhD · mette.oedegaard.nielsen@regionh.dk
Always discuss trial participation with your own doctor first.
| Mental Health Services Glostrup, Unit for Complicated Schizophrenia | Glostrup Municipality, Denmark, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05316883